EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study

Cristina Gavina iD, Daniel Seabra iD, Sílvia Oliveira, Carla Teixeira iD, Jorge A Ruivo iD, Nuno Lourenço-Silva iD, Ana Rita Luz iD, Cristina Jácome iD, Francisco Araújo iD

Global Heart · 27.03.2026 · 21 (1) · 29

DOI: 10.5334/gh.1543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Heart, online erschienen am 27.03.2026. Verfasst von Cristina Gavina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, ULS Matosinhos, 4464-513 Senhora da Hora, Matosinhos, Portugal. Hauptthemen laut MEDLINE: Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite clear guidelines for lipid-lowering therapies (LLT) for patients with high and very-high atherosclerotic cardiovascular disease (ASCVD) risk, a significant gap persists between recommended low-density lipoprotein cholesterol (LDL-C) management and actual clinical practice, leaving a large proportion of patients without adequate treatment. Patient age is one of several factors that may play a role in this gap.

Objectives

We characterized LLT prescription patterns among middle-aged and older adults with high and very-high ASCVD risk and estimated the effect of age in achieving LDL-C control.

Methods

This cohort study used electronic health records of a Portuguese healthcare institution from January 2012 to December 2022. Middle-aged (40–69 years) and older (70–85 years) patients with high and very-high ASCVD risk were analysed. Exposure consisted of LLT prescriptions. LLT prescriptions were characterized in six dynamic patterns based on statin intensity (high, moderate, low) and the addition of ezetimibe. Risk for LDL-C control at 150 and 360 days was compared between the two age cohorts using multivariate Cox regressions.

Results

A total of 36,866 patients were identified, accounting for 407,500 LLT prescriptions. High-intensity statins were more frequently prescribed to middle-aged patients (12.0% vs. 8.6% older), whereas older patients more often received low-intensity statins (8.6% vs. 5.9% middle-aged). The use of statin-ezetimibe combinations was low across all age groups (0.1–1.4%). At 150 and 360 days of follow-up, LDL-C targets were achieved in 2,661 (0.7%) and 14,047 (3.8%) prescriptions, respectively. Older patients had a 32% higher rate of reaching LDL-C goals at 150 days (HR = 1.32, 95% CI = 1.19–1.45) and 27% at 360 days (HR = 1.27, 95% CI = 1.19–1.35).

Conclusion

LDL-C control remains low in high- and very-high-risk patients from a Portuguese integrated health care unit, with particularly low achievement rates among middle-aged adults, despite their higher use of high-intensity LLT. These findings highlight the need for optimized treatment strategies, including age-specific approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsHumansAgedFemaleMiddle AgedMaleAge FactorsAged, 80 and overAdultPortugalEzetimibeRetrospective StudiesAnticholesteremic Agents

Stichwörter der Autor:innen

DyslipidemiaLDL-C managementPrimary careReal-world evidenceSecondary care

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeAnticholesteremic Agents

Autor:innen und Institutionen

  • Cardiology Department, ULS Matosinhos, 4464-513 Senhora da Hora, Matosinhos, Portugal.
  • Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal.
  • UnIC, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Department of Physiology and Cardiac Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Medical Affairs, Daiichi-Sankyo, Porto Salvo, Portugal.
  • Department of Medicine, Lisbon Medical School, University of Lisbon, Lisbon, Portugal.

ORCID-Profile: Cristina Gavina, Daniel Seabra, Carla Teixeira, Jorge A Ruivo, Nuno Lourenço-Silva, Ana Rita Luz, Cristina Jácome, Francisco Araújo

Zitieren

APA

Gavina, C., Seabra, D., Oliveira, S., Teixeira, C., Ruivo, J. A., Lourenço-Silva, N., Luz, A. R., Jácome, C., & Araújo, F. (2026). Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study. Global Heart, 21(1), 29. https://doi.org/10.5334/gh.1543

Vancouver

Gavina C, Seabra D, Oliveira S, Teixeira C, Ruivo JA, Lourenço-Silva N, et al. Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study. Global Heart. 2026;21(1):29. doi:10.5334/gh.1543

BibTeX
@article{Gavina2026,
  author = {Gavina, Cristina and Seabra, Daniel and Oliveira, Sílvia and Teixeira, Carla and Ruivo, Jorge A and Lourenço-Silva, Nuno and Luz, Ana Rita and Jácome, Cristina and Araújo, Francisco},
  title = {Impact of Age on Lipid-Lowering Therapy Prescriptions and LDL-Cholesterol Control: Insights from the PORTRAIT-DYS Study},
  journal = {Global Heart},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {29},
  doi = {10.5334/gh.1543}
}
Kostenlos starten →